Pharma/Biotech News
Subscribe to Pharma/Biotech News

The Lead

GeoVax HIV Vaccine Moves Forward

April 1, 2015 1:40 pm | News | Comments

GeoVax Labs, a biotechnology company developing human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate. Read more...

Pharmacist Group Says Members Shouldn't Aid in Executions

April 1, 2015 1:34 pm | by Julie Watson, The Associated Press | News | Comments

In a move that could heighten the hurdles faced by states attempting to execute prisoners, a...

Actavis Selling Australian Generic Drug Unit to Amneal

April 1, 2015 10:30 am | by Associated Press | News | Comments

Actavis PLC is selling its generic drug business in Australia to privately-held Amneal ...

Paracetamol is Ineffective for Lower Back Pain

April 1, 2015 10:19 am | News | Comments

Paracetamol is not effective in the treatment of spinal pain and provides negligible benefits...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Merck's HPV Vaccine Now Available in Canada

April 1, 2015 10:12 am | News | Comments

Merck, known as MSD outside the United States and Canada, announced that Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada.  

Pill Manufacturing – A Second Revolution?

April 1, 2015 9:56 am | by Paul Roossin, Science Director Nanotronics Imaging | Articles | Comments

Pills have been used to deliver a measured medicinal dose for over three millennia. When the British artist, inventor, and watchmaker William Brockedon produced a compression machine for graphite to produce a better pencil lead, his invention was noticed by a savvy pharmaceutical company who hired him to retool the instrument to produce tablets. Read more...

Quintiles, Quest to Join to Provide Global Clinical Trials Lab Services

March 31, 2015 11:38 am | News | Comments

Quintiles and Quest Diagnostics announced a definitive agreement to form a global clinical trials laboratory services business. Read more...


Merck Serono, Intrexon Agree to Develop, Commercialize CAR-T Therapy

March 31, 2015 10:21 am | News | Comments

Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. Read more...

Development, Commercialization of Antibacterial Drugs to Speed Up

March 31, 2015 10:12 am | News | Comments

The growing threat posed by multi-drug resistant gram-negative organisms (MDR-GNBs) is lending a sense of urgency to the development of antibacterial drugs worldwide. Upcoming regulatory reforms to lower R&D costs and provide incentives for new drug identification will create attractive opportunities for pharmaceutical manufacturers. Read more...

Big Data in Pathology - Why We Aren't There Yet

March 31, 2015 9:29 am | by Ralf Huss, M.D., Chief Medical Officer, Definiens | Articles | Comments

Medicine has lagged behind other industries with regards to using a big data approach, but this is rapidly changing. Read more...

BioDelivery Sciences’ Pain Treatment Fails Study

March 30, 2015 3:46 pm | by Stephanie Guzowski, Editor | News | Comments

BioDelivery Sciences International Inc. said on Monday its pain drug for diabetic neuropathy failed to meet the primary goal in a Phase 3 clinical trial. Shares fell nearly 30 percent. Read more...

Novartis, Aduro: Up-to-$750M Cancer Immunotherapy Collaboration

March 30, 2015 12:52 pm | by Stephanie Guzowski, Editor | News | Comments

Novartis is planning to boost its cancer immunotherapy pipeline with a collaboration with California-based Aduro Biotech worth up to $750 million. Read more...


Novo to Launch Novoeight in the U.S. for People With Hemophilia A

March 29, 2015 3:38 pm | News | Comments

The US Food and Drug Administration (FDA) approved Novoeight for use in adults and children with hemophilia A for the control and prevention of bleeding, perioperative management, and routine prophylaxis. Read more...

Meet the Head of Bayer's U.S. Science Hub: Chris Haskell

March 27, 2015 3:42 pm | by Ryan Bushey, Associate Editor | Articles | Comments

Haskell's role is to establish partnerships with life science startups working on intriguing projects. Read more...

Nanoparticle Therapy Promotes Wound Healing

March 27, 2015 2:00 pm | by Yeshiva University | News | Comments

An experimental therapy can cut in half the time it takes to heal wounds compared to no treatment at all. Read more...

Eisai Receives Japanese Approval for Anticancer Agent

March 27, 2015 1:40 pm | News | Comments

Eisai announced that it has received manufacturing and marketing authorization in Japan for its in-house developed novel anticancer agent. Read more...

Gelesis Closes $22M Equity Financing

March 27, 2015 10:21 am | News | Comments

Gelesis, a clinical stage biotechnology company focused on the development of first-in-class products to induce weight loss and improve glycemic control, announced today that it closed an equity financing of shares of convertible preferred stock for gross proceeds of approximately $22 million. Read more...


Novo Nordisk Resubmits NDA for Tresiba, Ryzodeg in U.S.

March 26, 2015 4:38 pm | News | Comments

The resubmission is expected to take place within the next month. Read more...

Takeda's NDA for Type 2 Diabetes Drug Gets Japanese Approval

March 26, 2015 4:26 pm | News | Comments

Zafatek is a once-weekly DPP-4 inhibitor.

FDA to Scrutinize Unproven Alternative Remedies

March 26, 2015 12:42 pm | by Matthew Perrone, AP Health Writer | News | Comments

Federal officials plan to review the safety and evidence behind alternative remedies like Zicam and Cold-Eeze, products that are protected by federal law, but not accepted by mainstream medicine. Read more...

Germany's Pharmaceutical Market Value will Crawl to $65B by 2020

March 26, 2015 11:38 am | by Joshua Owide, Director of Healthcare Industry Dynamics, GlobalData | Articles | Comments

Germany is a mature market with high healthcare expenditure and pharmaceutical production. Read more...

GSK Gains Japanese Approval for COPD Therapy

March 26, 2015 8:25 am | News | Comments

Following this approval, it is expected that launch will take place in Japan in 2015. Read more...

A Look at Some Key Statistics on Rare Diseases in the U.S.

March 25, 2015 1:45 pm | by The Associated Press | News | Comments

The global pharmaceutical industry is make huge investments in treatments for rare diseases, which once drew little interest from major drugmakers. Read more...

FDA Approves Anthrax Treatment

March 25, 2015 1:10 pm | by Stephanie Guzowski, Editor | News | Comments

The Food and Drug Administration (FDA) yesterday approved Emergent BioSolutions’ infusible drug Anthrasil for use in combination with antibiotics to treat inhalational anthrax, which happens when bacterial spores that carry anthrax are breathed in. Read more...

Sepsis-Specific Treatment Market Will Expand from 2016, Reach $354M by 2021

March 25, 2015 12:28 pm | by Marc C. Hansel, Ph.D., GlobalData Infectious Diseases Analyst | Articles | Comments

GlobalData's latest report states that this growth will be driven by the increased uptake of novel therapies. Read more...

Science, Patients Driving Rare Disease Drug Research Surge

March 25, 2015 11:34 am | by Linda A. Johnson, AP Business Writer | News | Comments

The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers but now point the way toward a new era of innovative therapies and big profits. Read more...

Antibiotics Pipeline Boasts 741 Products, but First-in-class Development Remains Low: GBI Research

March 25, 2015 9:48 am | News | Comments

While antibiotics boast a vast pipeline, with 741 products currently in development, the majority is dominated by generics, as weak financial incentives and high failure rates have discouraged innovation, says business intelligence provider GBI Research. Read more..

Non-FDA Approved Hormone Therapies on the Rise

March 25, 2015 9:36 am | by Cynthia Fox, Science Writer | Articles | Comments

Use of potentially risky, non-FDA approved hormone therapies may soon be as common as use of FDA-approved hormone therapies, according to a study by University of Virginia gynecology researcher JoAnn Pinkerton. Read more..

Blueprint Medicine Files for IPO

March 25, 2015 9:30 am | by Ryan Bushey, Associate Editor | Articles | Comments

The biotech firm is making a big bet on the success of its precision therapies. Read more...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.